Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
Key Highlights
- ➤OD-001 Phase 2a induction data to be presented orally at UEG Week 2026
- ➤Odyssey to host October 20 call reviewing additional OD-001 induction data
- ➤Presentation covers safety and efficacy in moderate-to-severe ulcerative colitis patients
- ➤Bruce Sands presents results at UEG Week on October 20
Expert Statements
Bruce Sands, M.D., M.S.; Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai
“Safety and Efficacy of OD-001, a First-in-class Oral RIPK2 Scaffolding Inhibitor, in Patients with Moderately to Severely Active Ulcerative Colitis: Results from a Phase 2a Trial”
Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT
BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at United European Gastroenterology (UEG) Week 2026, taking place October 17-20, in Barcelona, Spain.
Get started
Create a free account to read the full story.